When did Pacira BioSciences, Inc. report Q4 2024 earnings?

Pacira BioSciences, Inc. (PCRX) reported Q4 2024 earnings on February 27, 2025 after market close.

What were Pacira BioSciences, Inc.'s Q4 2024 revenue and EPS?

Pacira BioSciences, Inc. reported revenue of $187.3M and eps of $0.91 for Q4 2024.

Did Pacira BioSciences, Inc. beat estimates in Q4 2024?

Revenue beat the consensus estimate of $185.4M by $1.9M. EPS beat the consensus estimate of $0.78 by $0.13.

Where can I find Pacira BioSciences, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0001396814-25-000041) directly on SEC EDGAR. The filing index links above go to sec.gov.

Pacira BioSciences, Inc. PCRX Q4 2024 Annual earnings

Reported February 27, 2025 · After market close

Revenue$187.3MBeat by $1.9M

EPS$0.91Beat by $0.13

Revenue estimate$185.4M

EPS estimate$0.78

Next report

Aug 4, 2026 (In 6 days)

Revenue estimate$191.1M

EPS estimate$0.64

Financials

Q4 2024

Income statement

See full

Revenue$187.3M+3.3%

Gross profit$147.4M+10.3%

Balance sheet

See full

Cash & equivalents$276.8M+80.5%

Total debt$561.3M+199%

Total equity$778.3M-10.5%

Total assets$1.6B-1.3%

Cash flow

See full

Operating cash flow$33.1M-30.4%

CapEx$2.1M+17.8%

Free cash flow$31.0M-32.3%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$869.9M-44.5%

Enterprise value$1.15B-27.9%

P/S1.2×-1.1×

Profitability

See full

Gross margin75.7%+3.0pp

FCF margin25.5%+4.8pp

Returns & leverage

See full

Debt / equity0.7×+0.5×

Current ratio2.4×-2.8×

Segments

By product

See full

EXPAREL$147.7M+2.6%

ZILRETTA$33.1M+15.4%

iovera°$6.5M+6.9%

Bupivacaine liposome injectable suspension--100%

By segment

See full

Reportable Segment$187.3M+11.0%

Versus estimates

Revenue

Q1 2026$177.4MBeat by $5.6M Q4 2025$196.9MMiss by $3.5M Q3 2025$179.5MMiss by $22.4M Q2 2025$181.1MMiss by $1.3M Q1 2025$168.9MMiss by $18.6M

Q4 2024$187.3MBeat by $1.9M

Diluted EPS

Q1 2026$0.60Miss by $0.01 Q4 2025$0.57Miss by $0.28 Q3 2025$0.70Beat by $0.05 Q2 2025$0.74Beat by $0.02 Q1 2025$0.62Beat by $0.05

Q4 2024$0.91Beat by $0.13

Ask the moment Pacira BioSciences, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Pacira BioSciences, Inc. report Q4 2024 earnings?: Pacira BioSciences, Inc. (PCRX) reported Q4 2024 earnings on February 27, 2025 after market close.
What were Pacira BioSciences, Inc.'s Q4 2024 revenue and EPS?: Pacira BioSciences, Inc. reported revenue of $187.3M and eps of $0.91 for Q4 2024.
Did Pacira BioSciences, Inc. beat estimates in Q4 2024?: Revenue beat the consensus estimate of $185.4M by $1.9M. EPS beat the consensus estimate of $0.78 by $0.13.
Where can I find Pacira BioSciences, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0001396814-25-000041) directly on SEC EDGAR. The filing index links above go to sec.gov.